Lightnews — Scholar-powered news

Raunak Shrestha

@raunakms.bsky.social

120 followers 470 following 2 posts

Assistant Professor (incoming) CPDR/USUHS • PhD in Bioinformatics • Data Scientist • Cancer Genomics | MD, USA 🧬💻🔬 🇳🇵 🇨🇦 🇺🇸

Posts Replies Media Videos

Raunak Shrestha

@raunakms.bsky.social

WOW! visualizing #nucleosome via cryo-EM
Paper: Direct visualization and tracing of DNA fold in Drosophila embryo doi.org/10.1101/2022...

April 17, 2025 at 9:21 PM

Raunak Shrestha

@raunakms.bsky.social

The Genomic Revolution would not have happened without #NIH Funding to support ... #FundScience

April 2, 2025 at 1:45 AM

Reposted by Raunak Shrestha

PCF Science

@pcf-science.bsky.social

ANNOUNCEMENT: RFA for 2025 @PCFnews team science Challenge Award Applications, to support investigations of metastatic, lethal #ProstateCancer in 6 specified topic areas.

DEADLINE: May 5, 2025

Apply at: pcf.smartsimple.com

View the RFA: res.cloudinary.com/pcf/images/v...

Prostate Cancer Foundation 2025 PCF Challenge Awards For Metastatic, Lethal Prostate Cancer REQUEST FOR APPLICATIONS The Prostate Cancer Foundation (PCF) is pleased to announce a Request for Team Science Applications for PCF Challenge Awards for investigations of metastatic, lethal prostate cancer. These awards will be funded depending on the level of innovation in applications received. PCF seeks high-risk, currently unfunded projects from academic institutions around the world. PCF Challenge Awards: • Composed of a team of at least three (3) investigators from non-profit academic research centers, including one young investigator (see PCF Challenge Award Team requirements below). • Support large-scale research projects concerning metastatic, lethal prostate cancer over a duration of two years. • Provide up to a total of $1 million per team. • Cover only direct research costs and travel to the Annual PCF Scientific Retreat. • Clinical trial direct costs are not allowed; however, correlative research to support high impact clinical trials for advanced prostate cancer is encouraged. IRB submission and preferably approval is desired at time of application. • All studies involving patients must include plans for including diverse participant populations with appropriate representation of ethnic and racial minority groups. Comprehensive statistical plans and power calculations are required. Research proposals in the following topic areas are solicited: • Theranostics. • Drugging currently undruggable oncology targets: preventing progression to lethal disease. • Improved biotechnologies for precision medicine. • First-in-field immunotherapies for prostate cancer. • Artificial intelligence/machine learning to better inform patient outcomes. • Host microbiome and tumor metabolism.

March 20, 2025 at 4:53 PM

Reposted by Raunak Shrestha

Stegle Lab

@steglelab.bsky.social

1/ New preprint! 🍳

@elihei.bsky.social and our team at @embl.org , @dkfz.bsky.social, and @mskcancercenter.bsky.social built #segger - a fast, accurate cell segmentation tool for spatial transcriptomics that assigns transcripts to their cell origins!

doi.org/10.1101/2025...